Galapagos NV (AMS:GLPG) Stock Most Popular Amongst Retail Investors Who Own 56%, While Public Companies Hold 25%
Kepler Capital Remains a Sell on Galapagos (0JXZ)
Cautious Hold Rating for Galapagos: Unproven Efficacy and Logistical Concerns in CD19 CAR-T Programs
Galapagos Announced New Results From Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma; Demonstrated High Antitumor Activity And An Encouraging Safety Profile In All NHL Subtypes...
Galapagos' Innovative CAR T-Cell Therapy Shows Promise
Galapagos Downgraded to Reduce From Hold at Kepler Cheuvreux
whqqq : Thank you for your comprehensive sharing![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")